| Instead of introduction: an anniversary e-mail, signal of overviews |
| Chapter .I. ON THE BEES WORLD |
| I.1.CURIOSITIES OF BEES LIFE |
| I.2.KNOWN AND UNKNOWN ABOUT BEE GIFTS |
| Chapter II. APITHERAPY AND APITHERAPEUTIST |
| II.1. APITHERAPY BETWEEN THEORY AND PRACTICE |
| II.2. THE APITHERAPEUTIST |
| Chapter III. CONTRIBUTIONS FOR DEVELOPING THE APITHERAPY |
| III.1. MASTERS, DOCTORATES AND POSTDOCTORAL STUDIES |
| III.2. EDUCATIONAL CONTRIBUTIONS |
| III.3. PUBLISHING CONTRIBUTIONS |
| III.3.1. PUBLISHED BOOKS |
| III.3.2. PUBLISHED STUDIES AND ARTICLES |
| Chapter 4. PRODUCTION OF HONEY BEE THERAPEUTIC PRODUCTS |
| IV.1. THE NEED OF HONEY BEE THERAPEUTIC PRODUCTS |
| IV.2. THE HERITAGE |
| IV.3. BIOCHEMISTRY OF HONEY BEE PRODUCTS, SUPPORT OF HONEY BEE THERAPEUTIC RODUCTS PRODUCED BY APITHERAPY MEDUCAL CENTER |
| IV.3.1.BEE PRODUCTS. THEIR QUICK LOOK |
| IV.3.1.1. HONEY |
| IV.3.1.2. ROYAL JELLY |
| IV.3.1.3. APILARNIL |
| IV.3.1.4. POLLEN |
| IV.3.1.5. BEE BREAD |
| IV.3.1.6. PROPOLIS |
| IV.3.1.7. WAX |
| IV.3.1.8. BEE VENOM |
| IV.4. HONEY BEE PHARMACY AND HUMAN CELL |
| IV.4.1.HONEY BEE BIOMOLECULES - HUMAN CORRESPONDENCE |
| IV.4.2. HONEY BEE THERAPEUTIC PRODUCTS, HUMAN CELL AND EXTRACELLULAR ENVIRONMENT |
| IV.5. CHARACTERISTICS OF HONEY BEE THERAPEUTIC PRODUCTS PRODUCED BY APITHERAPY MEDICAL CENTER |
| IV.5.1. BINOMIAL CHARACTER OF HONEY BEE THERAPEUTIC PRODUCTS |
| IV.5.2. THREE DIMENSIONAL NATURE OF HONEY BEE THERAPEUTIC PRODUCTS |
| IV.5.3. SYNERGISTIC NATURE OF HONEY BEE THERAPEUTIC PRODUCTS |
| IV.5.3.1. BIOCHEMICAL OFFER SYNERGY OF HONEY BEE THERAPEUTIC PRODUCTS |
| IV.5.3.2. CLINICAL ACTION SYNERGY THROUGH PRESENCE SYNERGY |
| IV.5.3.2.1. AN EXAMPLE OF CLINICAL SYNERGY IN AUTOIMMUNITY |
| IV.5.3.3. HONEY BEE THERAPEUTIC PRODUCTS AND HONEY BEE STEM CELLS |
| IV.5.4. HONEY BEE THERAPEUTIC PRODUCTS PRODUCED BY APITHERAPY MEDICAL CENTER |
| Chapter V. OUR METHOD IN APIPROPHYLAXIS AND APITHERAPY |
| V.1. HEALTH, DISEASE, DIAGNOSIS |
| V.1.1. CLASSIFYNG THE DISEASES |
| V.2. CLINICAL APITHERAPY |
| V.3. CLINICAL APIPROPHYLAXIS |
| Chapter VI. - NOT TRANSLATED |
| VI.1. - Not translated |
| VI.1.1 - Not translated |
| VI.1.2 - Not translated |
| VI.1.2.1. - Not translated |
| VI.1.2.2. - Not translated |
| VI.1.2.3. - Not translated |
| VI.1.2.4. - Not translated |
| VI.1.2.5. - Not translated |
| VI.1.2.6. - Not translated |
| VI.2. - Not translated |
| Chapter VII. - The Laboratory Tests |
| VII.1. THE LABORATORY TESTS. SERUM PROTEIN ELECTROPHORESIS, IONIZED CALCIUM AND REBALANCING PLASMA PROTEINS |
| VII.1.2. ROUTINE LABORATORY TESTS |
| VII.1.3 SPECIALIST LABORATORY TESTS |
| VII.2. THE PROTEINS AND THE HOMEOSTASIS |
| VII.2.1. PROTEINAEMIA, TOTAL PROTEINS AND DYSPROTEINAEMIA. |
| VII.2.2. THE TOTAL PROTEINS – VALUES CONSIDERED TO BE NORMAL AND VALUES THAT WE PROPOSE TO BE ADOPTED AS NORMAL |
| VII.3. THE SERUM PROTEIN ELECTROPHORESIS AND IONIZED CALCIUM, VALUABLE TESTS FOR HEALTH |
| VII.3.1. ILLUSTRATIVE CLINICAL CASES FOR ESTABLISHING THE LIMITS OF THE NORMAL VALUES OF TOTAL AND SERUM PROTEINS |
| Uterine fibroma, autoimmune disease – 35 years old/ 1,56m/ 44 kg |
| Polycystic ovary � 18 years old/ 1,60 m/ 46 kg |
| Not translated |
| Not translated |
| Not translated |
| Not translated |
| Not translated |
| Not translated |
| Not translated |
| Not translated |
| Not translated |
| Not translated |
| Not translated |
| Not translated |
| Not translated |
| Not translated |
| Not translated |
| Not translated |
| Glioblastoma multiforme – Standard therapy and apitherapy Apitherapy clinical breakthrough |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
